Janet Woodcock, Paul Kim join Friends’ board of directors

Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines

Look at where our understanding of cancer was two, five, 10, 15, 20, or more years ago and then consider what has happened over the past two decades. We finally realized how more complex the problem of cancer is—more than any of us imagined.

Vinay Prasad regains role as FDA chief medical and scientific officer

Vinay Prasad has regained his role as FDA’s chief medical and scientific officer, according to an update on the agency’s website.

September 12, 2025

Vol.51 No.33

By Claire Marie Porter

Cancer Policy

FDA advances rare disease drug development with new evidence principles

FDA introduced the Rare Disease Evidence Principles to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.

Mark Foundation for Cancer Research, Samuel Waxman Cancer Research Foundation establish Aging & Cancer Institute

The Mark Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation announced they will combine in a first-of-its-kind transaction in cancer philanthropy to launch the Samuel Waxman Institute for Aging & Cancer.

September 12, 2025

Vol.51 No.33

In Brief

2025 Lasker awards announced

Top row (left to right): Dirk Görlich, Steven L. McKnight, Michael J. Welsh.Bottom row (left to right): Jesús (Tito) González, Paul A. Negulescu, Lucy ShapiroThe 2025 Albert Lasker Basic Medical Research Award honors went to two scientists for discoveries that exposed the structures and functions of low-complexity domains within protein sequences.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival improvement for patients with previously untreated locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, according to data from the phase III Mariposa study.

September 12, 2025

Vol.51 No.33

Janet Woodcock, Paul Kim join Friends’ board of directors

YOU MAY BE INTERESTED IN

Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines

Vinay Prasad regains role as FDA chief medical and scientific officer

FDA advances rare disease drug development with new evidence principles

Mark Foundation for Cancer Research, Samuel Waxman Cancer Research Foundation establish Aging & Cancer Institute

2025 Lasker awards announced

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Renew today!

Subscriber content

Never miss an issue!

Login

Janet Woodcock, Paul Kim join Friends’ board of directors

YOU MAY BE INTERESTED IN

Reflections of a cancer scientistMaintaining the pace of novel technologies will lead to more efficient and less toxic medicines

Vinay Prasad regains role as FDA chief medical and scientific officer

FDA advances rare disease drug development with new evidence principles

Mark Foundation for Cancer Research, Samuel Waxman Cancer Research Foundation establish Aging & Cancer Institute

2025 Lasker awards announced

Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows

Never miss an issue!

Login

Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines